Comparing severity in juvenile and adult dermatomyositis
Evaluation of Severity in Juvenile Dermatomyositis and Adult-onset Dermatomyositis: a National Multicentric Retrospective Study
Central Hospital, Nancy, France · NCT06004817
This study is trying to see how severe dermatomyositis is when first diagnosed in kids compared to adults, and how it changes over time for both groups.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France (other) |
| Locations | 1 site (Nancy) |
| Trial ID | NCT06004817 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate and compare the severity of dermatomyositis (DM) at initial diagnosis between juvenile and adult-onset patients. It focuses on assessing global severity as well as organ-specific severity, considering the unique characteristics and complications associated with each age group. The study will also track damage over time during follow-up. By gathering and analyzing this data, the research seeks to enhance understanding of the disease's impact across different age groups.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with dermatomyositis according to the 2017 ACR/EULAR classification criteria.
Not a fit: Patients with cancer-associated dermatomyositis or those with antisynthetase syndrome may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients with dermatomyositis.
How similar studies have performed: While there is limited data on the comparison of severity between juvenile and adult-onset DM, similar observational studies in autoimmune diseases have shown promise in understanding disease progression and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with dermatomyositis according to 2017 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification Exclusion Criteria: * Patient with cancer-associated dermatomyositis (within 3 years before or after diagnosis of dermatomyositis) * Patient with antisynthetase syndrome
Where this trial is running
Nancy
- Chu Nancy — Nancy, France (RECRUITING)
Study contacts
- Principal investigator: Paul Decker, MD — Central Hospital, Nancy, France
- Study coordinator: Paul Decker, MD
- Email: p.decker@chru-nancy.fr
- Phone: +33383157240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Dermatomyositis